YD Bio Limited is a biotechnology company that operates three complementary business segments: DNA methylation-based cancer diagnostic testing services delivered through CLIA-certified laboratory partners, life science clinical services including clinical trial supply chain support and logistics coordination for pharmaceutical and biotech companies, and healthcare product commercialization spanning ocular health products such as artificial tears and specialty eye drops in the United States and consumer health distribution in Asia. The company generates revenue through service fees from diagnostic testing, milestone and royalty payments from licensed technologies including cancer biomarker patents and exosome-based eye care formulations, and direct product sales. Its customers include pharmaceutical and biotechnology companies, healthcare providers and laboratories, ophthalmology markets, and consumer distribution partners across multiple geographies.